2015
Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancers
Hellmann MD, Sturm I, Trnkova ZJ, Lettieri J, Diefenbach K, Rizvi NA, Gettinger SN. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancers. Clinical Lung Cancer 2015, 16: 514-522. PMID: 26003007, PMCID: PMC4750397, DOI: 10.1016/j.cllc.2015.04.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Non-Small-Cell LungCisplatinContraindicationsDrug InteractionsFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingNeovascularization, PathologicPemetrexedPhenylurea CompoundsPyridinesSurvival AnalysisTreatment OutcomeConceptsEfficacy of regorafenibMedian progression-free survivalChemotherapy-naive patientsProgression-free survivalPhase I trialCell lung cancerLung cancerAcceptable tolerabilityPartial responsePotent antiangiogenic activityI trialStandard dosesPK interactionsAdvanced nonsquamous non-small cell lung cancerNonsquamous non-small cell lung cancerTreatment-related grade 3 adverse eventsNon-small cell lung cancerGrade 3 adverse eventsKinase inhibitorsAntiangiogenic activityMinor pharmacokinetic interactionCombination of bevacizumabAdvanced colorectal cancerGastrointestinal stromal tumorsAdverse events
2014
B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer
Gettinger S, Herbst RS. B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer. The Cancer Journal 2014, 20: 281-289. PMID: 25098289, DOI: 10.1097/ppo.0000000000000063.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerPhase III trialsCell lung cancerIII trialsPD-1Lung cancerClinical trialsPD-1/PD-L1 inhibitorsB7-H1/PDTumor PD-L1 expressionSevere autoimmune toxicityChemotherapy-naive patientsPD-L1 expressionPotential of immunotherapyPD-L1 inhibitorsDeath ligand 1Future clinical trialsNumber of antibodiesAutoimmune toxicityExpansion cohortBlockade therapyDurable responsesNSCLC patientsStandard therapy